A recent study from cancer researchers at the University of Alabama at Birmingham and Georgia State University has identified a new therapeutic target in quadruple-negative breast cancer, or QNBC, one of the deadliest and most aggressive treatment-resistant forms of breast cancer.
Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options.
New research shows that a rare group of pancreatic cancer patients responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type.
A potential treatment for glioblastoma crafted by scientists at The Wertheim UF Scripps Institute renders the deadly brain cancer newly sensitive to both radiation and chemotherapy drugs, and blocks the cancer’s ability to invade other tissue, a new study shows.
The National Comprehensive Cancer Network announces a new, interactive digital delivery format for the NCCN Clinical Practice Guidelines in Oncology.
City of Hope is using generative artificial intelligence to create operational efficiency, enable AI-driven patient personalization, improve access to clinical trials, and empower breakthrough research.
First-line rucaparib maintenance treatment provided a progression-free survival benefit vs placebo in newly diagnosed, advanced, high-grade ovarian cancer after front-line platinum-based chemotherapy.
Relapsed/refractory peripheral and cutaneous T-cell lymphomas are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell transplants, but the disease needs to be brought under control before patients can undergo this treatment.
Devanand Sarkar and a team of scientists at VCU Massey Comprehensive Cancer Center have discovered that the gene TAF2 plays a pivotal role in the growth of hepatocellular carcinoma. The researchers found that TAF2 is overexpressed in HCC patients compared to individuals with healthy livers, and that TAF2 regulates the survival of hepatocytes—the functional cells of the liver—and tumor formation. Their study—recently published in the journal Hepatology also demonstrates that TAF2 cooperates with the MYC gene, another known major driver of cancer, to accelerate tumor growth.
Little is known about what causes ovarian cancer, and there is no way to detect it early. Now, an accidental finding in a 22-year-old patient has given Mayo Clinic researchers a new lead.
